Dr. Steven A. Toenjes, MD

Dr. Toenjes practices at Baptist Neurology Inc in Jacksonville, Florida.

Dr. Toenjes' NPI, 1679585764, was assigned on August 13, 2006. Dr. Toenjes graduated from Wake Forest School of Medicine in 2002. Dr. Toenjes holds Florida license ME106566.

Dr. Toenjes' primary practice is Baptist Neurology Inc, at 7807 Baymeadows E Rd, Jacksonville, FL 32256 in Duval County. The practice phone is (904) 376-3707.

Dr. Toenjes' primary practice is Baptist Neurology Inc in Jacksonville, Florida. Dr. Toenjes is also affiliated with Baptist Medical Center Jacksonville. The medical group on file is Baptist Neurology. Dmand AI also links Dr. Toenjes to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Toenjes practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Toenjes' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Toenjes is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Toenjes' licenses on file in 2 states: Florida and Connecticut.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, cerebrovascular disease, epilepsy, essential tremor, fibromyalgia and chronic pain, hereditary polyneuropathy and hypersomnia among the conditions Dr. Toenjes treats.

CMS data shows 45,201 Medicare services from Dr. Toenjes across 11 procedure codes in 2024, for 560 Medicare patients. Medicare paid $311,788 for them.

CMS counts 560 Medicare patients who saw Dr. Toenjes in 2024. The largest group is 75 to 84, with 233 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Toenjes' median patient age at 68, with 64% women.

In 2024, Dr. Toenjes wrote 454 Medicare Part D claims for 148 patients. 56% of them were for generic drugs. CMS names the drug for 349 of them, across 12 drugs with 11 or more claims each, at $229,641 in total drug cost. In 2023, CMS named 400 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Toenjes for performance year 2024, reported as part of a group. Dr. Toenjes accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Toenjes in 2002. The most frequent topics are Cysticercosis, Cytokines and Interferon-gamma. Dr. Toenjes has published most often in Parasitology.

Dmand AI links Dr. Toenjes to 5 clinical trials. 2 are still active or recruiting. Conditions studied include Cognitive Dysfunction, Alzheimer Disease and Migraine without Aura. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Toenjes that name 3 trials.

CMS Open Payments shows 1,979 general payments to Dr. Toenjes from 78 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Amgen Inc. paid the most, $224,650. It also lists 7 research payments totaling $16,471 from 2021 to 2023, naming 3 clinical trials.

Dr. Toenjes graduated from Wake Forest School of Medicine in 2002.

Dr. Toenjes is in network with 15 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.